secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-009846
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics provides VMT-α-NET and pipeline updates; 76% progression-free in NET trial
--------------------------------------------------------------------------------

- VMT-α-NET Cohort 2: 19/25 pts (76%) progression-free at median ~13 wks additional follow-up vs ESMO 2025; 9/23 (39%) had RECIST response.
- Safety in 56 pts: no DLTs, no treatment-related discontinuations; Grade 3+ AEs in 37.5%, one transient Grade 4 lymphopenia.
- Cohort 3 (6.0 mCi) cleared by SMC after 8-patient DLT review; 9 patients treated as of Dec 31, 2025.
- VMT01 melanoma: 9 patients dosed at 3.0 mCi (5 with nivolumab, 4 monotherapy) as of Dec 31; data submission planned after 24-week follow-up.
- PSV359 FAP-targeting trial: 5 patients dosed across Cohort 1 (2.5 mCi) and Cohort 2 (5.0 mCi) with site activations underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000119312526009846/0001193125-26-009846-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000119312526009846/catx-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-009846

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer